Advertisement
Advertisement
TBPH
Theravance Biopharma, Inc.
17.01
USDSponsored
-0.01
-0.06%
May 08, 15:59 UTC -4
Closed
Pre-Market
17.21
+0.20
+1.18%
TBPH Earnings Reports
Positive Surprise Ratio
TBPH beat 17 of 41 last estimates.
41%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$20.40M
/$0.12
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
-22.12%
/-122.22%
Theravance Biopharma, Inc. earnings per share and revenue
On May 06, 2026, TBPH reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -0.14 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 17.54 million, with a --% difference.
Looking ahead to Q2 26, 7 analysts forecast an EPS of 0.12 USD, with revenue projected to reach 20.40 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Theravance Biopharma, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Theravance Biopharma, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Theravance Biopharma, Inc.'s Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Theravance Biopharma, Inc. expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Theravance Biopharma, Inc.'s next earnings report?
Based on 7
analysts, Theravance Biopharma, Inc. is expected to report EPS of $0.12 and revenue of $20.40M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement